Alternative dosing schedules for cetuximab: A role for biweekly administration?

Research output: Contribution to journalReview articlepeer-review

10 Scopus citations


The anti-epidermal growth factor receptor targeted monoclonal antibody (MoAb) cetuximab has established efficacy as a single agent and in combination with other modalities (chemotherapy, radiation therapy) in head and neck cancer and metastatic colorectal cancer. The agent is typically administered weekly; however, the development of a biweekly dosing regimen for cetuximab would provide treatment flexibility when combined with biweekly or longer chemotherapy regimens. The feasibility for biweekly dosing with cetuximab is supported by several factors. Biweekly dosing with MoAbs has been effective in multiple tumor types. Although cetuximab is currently administered on a weekly schedule, pharmacokinetic data demonstrate that cetuximab has a long terminal half-life, allowing administration of a biweekly schedule. Results from phase I studies show that a biweekly schedule of cetuximab is well tolerated, exhibits similar pharmacokinetics and pharmacodynamics to conventional weekly dosing, and does not seem to compromise efficacy. Additional studies are therefore warranted to further evaluate biweekly dosing for cetuximab in order to optimize treatment outcomes and convenience for patients.

Original languageEnglish (US)
Pages (from-to)364-368
Number of pages5
JournalClinical colorectal cancer
Issue number6
StatePublished - Nov 2008


  • EGFR
  • Monoclonal antibody
  • Squamous cell carcinoma of the head and neck

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology


Dive into the research topics of 'Alternative dosing schedules for cetuximab: A role for biweekly administration?'. Together they form a unique fingerprint.

Cite this